Silvant Capital Management LLC Buys Shares of 45,399 Natera, Inc. $NTRA

by · The Markets Daily

Silvant Capital Management LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 45,399 shares of the medical research company’s stock, valued at approximately $12,324,000.

Other institutional investors have also modified their holdings of the company. Integrated Wealth Concepts LLC grew its position in shares of Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares during the period. NewEdge Advisors LLC raised its holdings in Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares during the period. Focus Partners Wealth raised its holdings in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after acquiring an additional 474 shares during the period. Sivia Capital Partners LLC bought a new stake in shares of Natera in the second quarter valued at about $298,000. Finally, WINTON GROUP Ltd bought a new stake in Natera in the 2nd quarter valued at approximately $558,000. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ NTRA opened at $324.84 on Friday. The stock’s fifty day moving average price is $271.84 and its two-hundred day moving average price is $228.67. Natera, Inc. has a one year low of $157.43 and a one year high of $333.56. The firm has a market cap of $46.82 billion, a price-to-earnings ratio of -238.85 and a beta of 1.51.

Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. During the same quarter last year, the business earned ($0.74) EPS. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. On average, equities analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Natera news, Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the sale, the director owned 6,183 shares of the company’s stock, valued at $1,343,009.43. The trade was a 64.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the transaction, the chief executive officer owned 108,743 shares in the company, valued at approximately $24,035,465.29. The trade was a 27.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 181,045 shares of company stock valued at $41,330,968 in the last three months. Insiders own 5.05% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several analyst reports. Citigroup boosted their price target on shares of Natera from $315.00 to $365.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. BTIG Research increased their price target on Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Guggenheim raised their price target on Natera from $290.00 to $360.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Leerink Partners set a $330.00 price objective on shares of Natera in a research report on Friday, August 7th. Finally, Wells Fargo & Company lifted their price objective on shares of Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $319.38.

Get Our Latest Report on Natera

About Natera

(Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Read More

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).